Jiang J, Warren C, Browning R, Ciaccio C, Gupta R. Food allergy: epidemiology and racial/ethnic differences. J Food Allergy. 2020;1:xx–xx.

Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics [Internet]. 2011;128. Available from: https://doi.org/10.1542/peds.2011-0204.

Gupta RS, Springston EE, Warrier MR, Smith B, Kumar R, Pongracic J, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics [Internet]. [cited 2017 Jan 17] 2011;128(1):e9–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21690110.

Skolnick HS, Conover-Walker MK, Koerner CB, Sampson H a, Burks W, Wood R a. The natural history of peanut allergy. J Allergy Clin Immunol [Internet]. [cited 2011 Feb 27] 2001;107(2):367–74. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11174206.

Cianferoni A, Muraro A. Food-induced anaphylaxis. Immunol Allergy Clin North Am [Internet]. 2012;32(1):165–95. Available from: https://doi.org/10.1016/j.iac.2011.10.002.

Sicherer SH, Sampson H a. Food allergy: epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol [Internet]. [cited 2014 Jan 21] 2013;133(2):291–307.e5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24388012.

Yu JW, Kagan R, Verreault N, Nicolas N, Joseph L, St Pierre Y, et al. Accidental ingestions in children with peanut allergy. J Allergy Clin Immunol [Internet]. [cited 2011 Apr 7] 2006;118(2):466–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16890773.

Capucilli P, Wang KY, Spergel JM. Food reactions during avoidance: focus on peanut. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2020;124(5):459–65.

Article  CAS  Google Scholar 

• Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Hourihane JO, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379(21):1991–2001. A seminal multi-center trial of peanut oral immunotherapy safety and efficacy.

Article  PubMed  Google Scholar 

Chinthrajah RS, Purington N, Andorf S, Long A, O’Laughlin KL, Lyu SC, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2019;394(10207):1437–49.

Article  PubMed  PubMed Central  Google Scholar 

Varshney P, Jones SM, Pons L, Kulis M, Steele PH, Kemper AR, et al. Oral immunotherapy (OIT) induces clinical tolerance in peanut-allergic children. J Allergy Clin Immunol [Internet]. 2009 Feb;123(2, Supplement 1):S174–S174. Available from: http://www.sciencedirect.com/science/article/B6WH4-4VK8XCP-VB/2/0f2f1dbfefe726176b9e642b62f558b5.

Anagnostou K, Islam S, King Y, Foley L, Pasea L, Bond S, et al. Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial. Lancet [Internet]. 2014 Jan 29 [cited 2014 Feb 19];6736(Stop Ii):1–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24485709.

Hourihane JO, Beyer K, Abbas A, Fernández-Rivas M, Turner PJ, Blumchen K, et al. Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Child Adolesc Health. 2020;4(10):728–739.

Jones SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet [Internet]. 2022;399(10322):359–71. Available from: https://doi.org/10.1016/S0140-6736(21)02390-4.

Blackman AC, Anagnostou A. Identification of goals and barriers to treatment from 92 consecutive consultations with families considering peanut oral immunotherapy. Ther Adv Vaccines Immunother. 2019;7:2515135519869763.

PubMed  PubMed Central  Google Scholar 

Patrawala S, Ramsey A, Capucilli P, Tuong L-A, Vadamalai K, Mustafa SS. Real-world adoption of FDA-approved peanut oral immunotherapy with palforzia. J Allergy Clin Immunol Pract. 2022;10(4):1120-1122.e1.

Article  PubMed  CAS  Google Scholar 

Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, et al. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol [Internet]. 2016; Available from: https://doi.org/10.1016/j.jaci.2016.05.027.

Herlihy L, Kim EH, Burks AW, Barber H, Cook Q, Yang L, et al. Five-year follow-up of early intervention peanut oral immunotherapy. J Allergy Clin Immunol Pract [Internet]. 2020; Available from: http://www.sciencedirect.com/science/article/pii/S2213219820307170.

Soller L, Abrams EM, Carr S, Kapur S, Rex GA, Leo S, et al. First real-world safety analysis of preschool peanut oral immunotherapy. J Allergy Clin Immunol Pract. 2021;9(3):1349–1356.e1.

• Jones SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study. Lancet [Internet]. 2022;399(10322):359–71. Available from: https://doi.org/10.1016/S0140-6736(21)02390-4. A key study on early life peanut oral immunotherapy.

Chu DK, Wood RA, French S, Fiocchi A, Jordana M, Waserman S, et al. Oral immunotherapy for peanut allergy ( PACE ): a systematic review and meta-analysis of e ffi cacy and safety. Lancet. 2019;6736(19):1–11.

Google Scholar 

Eiwegger T, Anagnostou K, Arasi S, Begin P, Ben-Shoshan M, Beyer K, et al. ICER report for peanut OIT comes up short. Ann Allergy Asthma Immunol. 2019;123(5):430–432.

Patel N, Vazquez-Ortiz M, Turner PJ. Risk factors for adverse reactions during OIT. Curr Treat Options Allergy. 2019;6(2):164–74.

Article  Google Scholar 

Virkud Y, Vickery BP, Steele PH, Kulis MD, Burks AW. Predictors of elevated rates of adverse events while on peanut oral immunotherapy. J Allergy Clin Immunol [Internet]. 2015;135(2):AB156. Available from: https://doi.org/10.1016/j.jaci.2014.12.1450.

Varshney P, Steele PH, Vickery BP, Bird JA, Thyagarajan A, Scurlock AM, et al. Adverse reactions during peanut or0061l immunotherapy home dosing. J Allergy Clin Immunol [Internet]. [cited 2010 Sep 23] 2009;124(6):1351–2. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2794892&tool=pmcentrez&rendertype=abstract.

• Anagnostou K, Clark a, King Y, Islam S, Deighton J, Ewan P. Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome. Clin Exp Allergy [Internet]. [cited 2011 Mar 22] 2021;1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21414048. A key study on factors predicting peanut oral immunotherapy outcomes.

Dua S, Ruiz-Garcia M, Bond S, Durham SR, Kimber I, Mills C, et al. Effect of sleep deprivation and exercise on reaction threshold in adults with peanut allergy: A randomized controlled study. J Allergy Clin Immunol. 2019;144(6):1584-1594.e2.

Article  PubMed  PubMed Central  Google Scholar 

Vickery BP, Vereda A, Nilsson C, du Toit G, Shreffler WG, Burks AW, et al. Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study. J Allergy Clin Immunol Pract. 2021;9(5):1879-1889.e14.

Article  PubMed  CAS  Google Scholar 

Santos AF, Du Toit G, O’Rourke C, Becares N, Couto-Francisco N, Radulovic S, et al. Biomarkers of severity and threshold of allergic reactions during oral peanut challenges. J Allergy Clin Immunol. 2020;146(2):344–55.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Dreskin SC, Germinaro M, Reinhold D, Chen X, Vickery BP, Kulis M, et al. IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2019;30(8):817–23.

Article  Google Scholar 

Loke P, Orsini F, Lozinsky AC, Gold M, O’Sullivan MD, Quinn P, et al. Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial. Lancet Child Adolesc Heal. 2022;6(3):171–84.

Article  CAS  Google Scholar 

Schneider LC, Rachid R, Lebovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132(6):1368–74.

Article  PubMed  PubMed Central  CAS  Google Scholar 

MacGinnitie AJ, Rachid R, Gragg H, Little SV, Lakin P, Cianferoni A, et al. Omalizumab facilitates rapid oral desensitization for peanut allergy. J Allergy Clin Immunol. 2017;139(3):873-881.e8.

Article  PubMed  CAS  Google Scholar 

Dantzer JA, Wood RA. Omalizumab as an adjuvant in food allergen immunotherapy. Curr Opin Allergy Clin Immunol [Internet]. 2021;21(3). Available from: https://journals.lww.com/co-allergy/Fulltext/2021/06000/Omalizumab_as_an_adjuvant_in_food_allergen.9.aspx. Accessed 27 June 2022.

Sampson H a. Update on food allergy. J Allergy Clin Immunol [Internet]. 2004;113(5):805–19; quiz 820. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15131561. Accessed 20 July 2022.

Anagnostou K, Swan K, Fox AT. Recent advances in management of pediatric food allergy. Children (Basel). 2015;2(4):439–452.

Shaker MS, Wallace D V, Golden DBK, Oppenheimer J, Bernstein JA, Campbell RL, et al. Anaphylaxis - a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. J Allergy Clin Immunol [Internet]. 2020; Available from: https://doi.org/10.1016/j.jaci.2020.01.017.

ASCIA. Acute Management of Anaphylaxis [Internet]. 2017. Available from: https://www.allergy.org.au/health-professionals/papers/acute-management-of-anaphylaxis-guidelines. Accessed 27 June 2022.

Muraro A, Halken S, Arshad SH, Beyer K, Dubois AEJ, Du Toit G, et al. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy. 2014;69(5):590–601.

Simons FER, Ardusso LRF, Bilò MB, Dimov V, Ebisawa M, El-Gamal YM, et al. 2012 Update: World Allergy Organization guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol [Internet]. 2012;12(4):389–99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22744267. Accessed 16 June 2022.

Li X, Ma Q, Yin J, Zheng Y, Chen R, Chen Y, et al. A clinical practice guideline for the emergency management of anaphylaxis (2020). Front Pharmacol. 2022;13:845689.

Article  PubMed  PubMed Central  Google Scholar 

Chinthrajah RS, Jones SM, Kim EH, Sicherer SH, Shreffler W, Lanser BJ, et al. Updating the CoFAR Grading Scale for systemic allergic reactions in food allergy. J Allergy Clin Immunol [Internet]. 2022;149(6):2166–2170.e1. Available from: https://doi.org/10.1016/j.jaci.2021.12.789. Accessed 7 June 2022.

Ewan PW, Clark AT. Long-term prospective observational study of patients with peanut and nut allergy after participation in a management plan. Lancet. 2001;357(9250):111–5.

Article  PubMed  CAS  Google Scholar 

Sampson HA. Anaphylaxis and emergency treatment. Pediatrics. 2003;111(6 III):1601–8.

Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J [Internet]. 2020;13(10):100472. Available from: https://doi.org/10.1016/j.waojou.2020.100472.

Arasi S, Nurmatov U, Turner PJ, Ansotegui IJ, Daher S, Dunn-Galvin A, et al. Consensus on DEfinition of Food Allergy SEverity (DEFASE): protocol for a systematic review. World Allergy Organ J. 2020;13(12):100493.

Article  PubMed  PubMed Central  Google Scholar